CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Background/Aim: To evaluate the optimal dosage of rabeprazole for proton-pump inhibitor (PPI)
testing of gastroesophageal reflux disease (GERD) and to test the influence of cytochrome P
(CYP) 2C19 polymorphism in a population with a high prevalence of people who poorly
metabolize PPIs.
Patients and Methods: In this randomized, open-label trial, patients with symptoms suggestive
of GERD were randomized to receive a two-week test with 20-mg or 40-mg rabeprazole after
diagnostic endoscopy. Symptom response was assessed with a four-grade daily record; in
addition, DNA from peripheral blood leukocytes was genotyped for CYP2C19 polymorphism with
polymerase chain reaction-restrict fragment length polymorphism (PCR-RFLP) technique.